Tristel Regulatory News (TSTL)

TRISTEL plc

("Tristel" or the "Company")

APIC25 Annual Conference attendance

Tristel Exhibits at the Largest Annual Infection Prevention Event in the U.S. and Launches Tristel OPH Following FDA Clearance

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces its successful participation at APIC 2025, the largest annual infection prevention and control conference in the United States, and the official U.S. launch of Tristel OPH, a novel high-level disinfectant for ophthalmic instruments, following clearance by the U.S. Food and Drug Administration (FDA).

APIC 2025 provided a high-impact platform for Tristel to introduce Tristel OPH to the U.S. market. The product addresses a significant unmet need in ophthalmology, offering a solution that combines compliance with infection control guidelines and improved clinical workflow efficiency. Its debut generated exceptional interest from infection prevention professionals, reflecting the urgency for effective, practical alternatives in the reprocessing of ophthalmic medical devices.

A robust pipeline of prospective customers has already been established, with many health systems engaging directly with the Tristel team during the event for live demonstrations and discussions on product evaluation. Stock availability is expected in August 2025, and Tristel is actively supporting U.S. institutions in preparing for clinical trials and internal validation upon launch.

In addition to Tristel OPH, the Company also showcased Tristel ULT, its FDA-cleared high level disinfectant for ultrasound probes, represented by Tristel's distribution partner and ultrasound specialist, Parker Laboratories, Inc., and Tristel 3T, the Company's digital traceability platform. Both products attracted strong interest from new prospects and existing users alike, with particular enthusiasm shown for Tristel ULT's cost-effectiveness and rapid reprocessing capabilities.

The strong reception at APIC 2025 reinforces Tristel's accelerating momentum in the U.S. and underlines the increasing demand for innovative and compliant high level disinfection solutions in medical device reprocessing.

 [

Matt Sassone, CEO of Tristel plc, said: "APIC 2025 marked a significant milestone for our U.S. strategy. The FDA clearance and now successful launch of Tristel OPH opens a valuable new market in ophthalmology and demonstrates our ability to deliver meaningful innovation where it's urgently needed. The response to both Tristel OPH and Tristel ULT was overwhelmingly positive, and we are excited about the opportunities ahead."

For further information please contact:

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com